

Technology Appraisal Committee A Interests Register

Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]

Publication Date: 12 March 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dominic Pivonka	Committee Member	Indirect – Financial interests	Dominic's employer (AbbVie) has a treatment entering a phase 2 trial in locally advanced unresectable or metastatic gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma	10/12/2024	It was agreed that Dominic's declaration would not prevent him from being part of the committee.
James Fotheringham	Committee Member	Indirect - Financial Interests	James has undertaken systematic review work in the disease space of hypertension, paid to his employer.	10/12/2024	It was agreed that James' declaration would not prevent him from being part of the committee.
David Chuter	Clinical Expert	Indirect	Board member - Digestive Cancers Europe, September 2022 – current. Unpaid Director - Use MY data, May 2021 – current.	07/08/2024	It was agreed that David Chuter's declaration would not prevent him from providing expert advice to the committee.
Dr Martin Scott – Brown	Clinical Expert	Direct – financial	Dr Scott Brown has received payment from Astellas for Advisory board work and in preparation for this HTA submission. Total amount received from Astellas between Feb-2023 and Feb-2024 was	07/08/2024	It was agreed that Dr Scott Brown's declaration would not prevent him from providing expert advice to the committee.



			£1,133. He has also received payment from other pharmaceutical companies including MSD, BMS, Merck and Servier for advisory work and chairing and speaking at educational meetings.		
Dr Agnieszka Michael	Clinical expert	Direct – financial	Participation in advisory boards	11/06/2024	It was agreed that Dr Michael's declaration would not prevent her from providing expert advice to the committee.